SHANGHAI, China, April 7, 2008 /Xinhua-PRNewswire-FirstCall/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced it was awarded the 2007 Chemistry CRO of the Year Award by the Pfizer Chemistry Sourcing Center of Emphasis (CoE).
(Logo: http://www.prnasia.com/sa/200708281726.jpg )
Dr. Richard Connell, Head of the Chemistry Sourcing CoE, presented the award plaque to Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, at a recent Steering Committee meeting held in Groton, Connecticut. WuXi PharmaTech has enjoyed a close and cooperative relationship with Pfizer for many years, with collaborations ranging from synthetic chemistry, parallel medicinal chemistry (PMC), and ADME to bioanalytical services. The award recognizes in particular the outstanding collaboration of the WuXi and Pfizer teams in an effort to shorten the cycle times between requests for and delivery of parallel medicinal chemistry.
Pfizer's Centers of Emphasis state their mission as "Delivering Value Through Partnership." The success of their partnership with WuXi was certainly reflected in this year's presentation of their Top Chemistry CRO Award.
As the largest pharmaceutical, biotechnology and medical device contract research organization, WuXi collaborates with Pfizer in a number of drug discovery and development areas. Dr. Gonghua Pan of Pfizer, a key member of the collaboration, commented on the impact, "With WuXi's help, we reduced the average time from submitting the request to shipping of the finished product from 65 days in 2006 to 43 days in 2007, and at no increase in cost. This improvement reflects their own corporate commitment to continuous improvement - a commitment embedded in their slogan, 'we are determined to serve you better(R).'"
"We are very honored to receive this recognition from Pfizer, one of our largest customers for many years, and we really appreciate the trust and support Pfizer has given us. In order to better serve our customers we are building a global service and resource platform that has both small molecule and biologics capabilities covering early stage discovery to commercial manufacturing. By continuously improving our services and operation excellence, we will live up to our service creed 'We are determined to serve you better(R),'" commented Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.
About WuXi PharmaTech
WuXi PharmaTech, headquartered in Shanghai, China, is a leading global pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the U.S. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to pharmaceutical, biotechnology and medical device companies. Our services are designed to assist our global customers in shortening the time and lowering the cost of drug and medical device R&D by providing
cost-effective and efficient outsourcing solutions. For more information, please visit: http://www.wuxipharmatech.com .
